Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Detalles Bibliográficos
Autores principales: Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of European Society for Medical Oncology. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326208/
https://www.ncbi.nlm.nih.gov/pubmed/34352377
http://dx.doi.org/10.1016/j.annonc.2021.07.015
Descripción
Sumario:

Ejemplares similares